These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 28357504

  • 1. Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD65-induced immune response.
    Tavira B, Cheramy M, Axelsson S, Åkerman L, Ludvigsson J, Casas R.
    Diabetologia; 2017 Jul; 60(7):1276-1283. PubMed ID: 28357504
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. GAD treatment and insulin secretion in recent-onset type 1 diabetes.
    Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R.
    N Engl J Med; 2008 Oct 30; 359(18):1909-20. PubMed ID: 18843118
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial.
    Elding Larsson H, Lundgren M, Jonsdottir B, Cuthbertson D, Krischer J, DiAPREV-IT Study Group.
    Pediatr Diabetes; 2018 May 30; 19(3):410-419. PubMed ID: 29171140
    [Abstract] [Full Text] [Related]

  • 6. Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.
    Puente-Marin S, Dietrich F, Achenbach P, Barcenilla H, Ludvigsson J, Casas R.
    Front Immunol; 2023 May 30; 14():1112570. PubMed ID: 36817467
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.
    Ludvigsson J, Krisky D, Casas R, Battelino T, Castaño L, Greening J, Kordonouri O, Otonkoski T, Pozzilli P, Robert JJ, Veeze HJ, Palmer J, Samuelsson U, Elding Larsson H, Åman J, Kärdell G, Neiderud Helsingborg J, Lundström G, Albinsson E, Carlsson A, Nordvall M, Fors H, Arvidsson CG, Edvardson S, Hanås R, Larsson K, Rathsman B, Forsgren H, Desaix H, Forsander G, Nilsson NÖ, Åkesson CG, Keskinen P, Veijola R, Talvitie T, Raile K, Kapellen T, Burger W, Neu A, Engelsberger I, Heidtmann B, Bechtold S, Leslie D, Chiarelli F, Cicognani A, Chiumello G, Cerutti F, Zuccotti GV, Gomez Gila A, Rica I, Barrio R, Clemente M, López Garcia MJ, Rodriguez M, Gonzalez I, Lopez JP, Oyarzabal M, Reeser HM, Nuboer R, Stouthart P, Bratina N, Bratanic N, de Kerdanet M, Weill J, Ser N, Barat P, Bertrand AM, Carel JC, Reynaud R, Coutant R, Baron S.
    N Engl J Med; 2012 Feb 02; 366(5):433-42. PubMed ID: 22296077
    [Abstract] [Full Text] [Related]

  • 9. Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.
    Axelsson S, Chéramy M, Akerman L, Pihl M, Ludvigsson J, Casas R.
    Diabetes Care; 2013 Nov 02; 36(11):3418-24. PubMed ID: 23863909
    [Abstract] [Full Text] [Related]

  • 10. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response.
    Chéramy M, Skoglund C, Johansson I, Ludvigsson J, Hampe CS, Casas R.
    Clin Immunol; 2010 Oct 02; 137(1):31-40. PubMed ID: 20580618
    [Abstract] [Full Text] [Related]

  • 11. A/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed in conjunction with the Pandemrix vaccination campaign in Sweden 2009-2010.
    Lind A, Ramelius A, Olsson T, Arnheim-Dahlström L, Lamb F, Khademi M, Ambati A, Maeurer M, Nilsson AL, Bomfim IL, Fink K, Lernmark Å.
    J Autoimmun; 2014 May 02; 50():99-106. PubMed ID: 24485154
    [Abstract] [Full Text] [Related]

  • 12. Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes.
    Tavira B, Barcenilla H, Wahlberg J, Achenbach P, Ludvigsson J, Casas R.
    J Diabetes Res; 2018 May 02; 2018():9391845. PubMed ID: 30009185
    [Abstract] [Full Text] [Related]

  • 13. GAD-specific T cells are induced by GAD-alum treatment in Type-1 diabetes patients.
    Pihl M, Barcenilla H, Axelsson S, Chéramy M, Åkerman L, Johansson I, Ludvigsson J, Casas R.
    Clin Immunol; 2017 Mar 02; 176():114-121. PubMed ID: 28131926
    [Abstract] [Full Text] [Related]

  • 14. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65).
    Axelsson S, Hjorth M, Akerman L, Ludvigsson J, Casas R.
    Diabetes Metab Res Rev; 2010 Oct 02; 26(7):559-68. PubMed ID: 20830731
    [Abstract] [Full Text] [Related]

  • 15. Immune response differs between intralymphatic or subcutaneous administration of GAD-alum in individuals with recent onset type 1 diabetes.
    Dietrich F, Barcenilla H, Tavira B, Wahlberg J, Achenbach P, Ludvigsson J, Casas R.
    Diabetes Metab Res Rev; 2022 Mar 02; 38(3):e3500. PubMed ID: 34611978
    [Abstract] [Full Text] [Related]

  • 16. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
    Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet GAD Study Group.
    Lancet; 2011 Jul 23; 378(9788):319-27. PubMed ID: 21714999
    [Abstract] [Full Text] [Related]

  • 17. Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial).
    Casas R, Dietrich F, Puente-Marin S, Barcenilla H, Tavira B, Wahlberg J, Achenbach P, Ludvigsson J.
    Acta Diabetol; 2022 May 23; 59(5):687-696. PubMed ID: 35098372
    [Abstract] [Full Text] [Related]

  • 18. Antibodies to influenza virus A/H1N1 hemagglutinin in Type 1 diabetes children diagnosed before, during and after the SWEDISH A(H1N1)pdm09 vaccination campaign 2009-2010.
    Svensson M, Ramelius A, Nilsson AL, Delli AJ, Elding Larsson H, Carlsson A, Forsander G, Ivarsson SA, Ludvigsson J, Kockum I, Marcus C, Samuelsson U, Örtqvist E, Lernmark Å, Better Diabetes Diagnosis (BDD) study group.
    Scand J Immunol; 2014 Feb 23; 79(2):137-48. PubMed ID: 24313339
    [Abstract] [Full Text] [Related]

  • 19. Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients.
    Casas R, Dietrich F, Barcenilla H, Tavira B, Wahlberg J, Achenbach P, Ludvigsson J.
    Front Immunol; 2020 Feb 23; 11():564921. PubMed ID: 33162978
    [Abstract] [Full Text] [Related]

  • 20. Pandemrix® vaccination is not associated with increased risk of islet autoimmunity or type 1 diabetes in the TEDDY study children.
    Elding Larsson H, Lynch KF, Lönnrot M, Haller MJ, Lernmark Å, Hagopian WA, She JX, Simell O, Toppari J, Ziegler AG, Akolkar B, Krischer JP, Rewers MJ, Hyöty H, TEDDY Study Group.
    Diabetologia; 2018 Jan 23; 61(1):193-202. PubMed ID: 28990147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.